Hints and tips:
Showing results for Posey v. Qualitest Pharmaceuticals Inc
Related Special Reports
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...Aberdeen Asset Management and Canada Pension Plan have also voiced opposition to the deal, as has the local company Ilsung Pharmaceuticals, which holds 2 per cent....
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
...Just one of hundreds of raids carried out worldwide through Interpol’s Operation Pangea V, nearly 200 police and regulatory agencies combined efforts to clamp down on the complex multimillion dollar international...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Mr Paracuelles said he expected Japan to stage a V-shaped recovery in the second half of the year which would buoy Singapore’s economy....
...Apax is confident of raising a similar-sized fund to its last one, thanks to the €3.4bn it has returned to investors from realisations this year, including the $1.2bn sale of Qualitest Pharmaceuticals, the...
...Apax Partners of the UK has made a return of about 1.7 times its initial investment from the $1.2bn sale of Qualitest Pharmaceuticals, the US generic drugmaker, to its Nasdaq-listed rival Endo Pharmaceuticals...
...Examples include Astellas Pharma of Japan’s $3.8bn acquisition of OSI Pharmaceuticals in the US, and Korea National Oil’s $2.8bn deal with Britain’s Dana Petroleum....
...In deals news, Endo Pharmaceuticals Holdings surged 8.1 per cent to $33.10 after it said it will buy privately owned generic drug manufacturer Qualitest Pharmaceuticals for about $1.2bn....
...Economists dispute the nature of the recovery – is it a bounce-back “v” or a double-dip “w” – while old market hands caution that the summer rally could eventually give way to a correction....
...The US Supreme Court decided to intervene in several important business disputes, on Friday, including lawsuits that could be worth billions of dollars to pharmaceutical and tobacco companies....
...Meanwhile Schering-Plough, its closest competitor for the US pharmaceutical limelight, got a slap in the face as slackening market share gains by its top cholesterol drugs extinguished high hopes for the...
...He has consulted frequently on both pharmaceutical and high tech issues....
International Edition